Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia

Journal of Cardiac Failure

Volumn 18, Issue 8, 2012, Pages 607-613

  El Shitany, Nagla A ^a,b   Tolba, Osama A ^c   El Shanshory, Mohamed R ^c   El Hawary, Eslam E ^c  

^a TANTA UNIVERSITY   (Egypt)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

Adriamycin; carvedilol; echocardiography; leukemia

Indexed keywords

ASPARAGINASE; CARVEDILOL; CREATINE KINASE; CYTARABINE; DOXORUBICIN; HYDROCORTISONE; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; TROPONIN I; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOPPLER ECHOCARDIOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFECT; HEART CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; PREMEDICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ANTIBIOTICS, ANTINEOPLASTIC; CARBAZOLES; CHILD; CHILD WELFARE; DOXORUBICIN; FEMALE; HUMANS; MALE; PEDIATRICS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPANOLAMINES; TIME FACTORS; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84864436108     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2012.06.416     Document Type: Article

References (32)

1. H. Curry, S. Parkes, J. Powell, and J.R. Mann Caring for survivors of childhood cancers: the size of the problem Eur J Cancer 42 2006 501 508
2. E. Redha, S. Alsaad, and A. Alhassan Efficacy of carvedilol in the treatment of doxorubicin induced cardiomyopathy in a pediatric patient Kuwait Med J 37 2005 56 58
3. A. Kruger, and L. Wojnowski Cardiotoxicity of anthracyclines-an unsolved problem Dtsch Arztebl 103 2006 A2393 A2397
4. V. Machado, A. Cabral, P. Monteiro, L. Gonçalves, and L.A. Providência Carvedilol as a protector against the cardiotoxicity induced by anthracyclines (doxorubicin) Rev Port Cardiol 27 2008 1277 1296
5. R.D. Olson, and P.S. Mushlin Doxorubicin cardiotoxicity: analysis of prevailing hypotheses FASEB J 4 1990 3076 3086
6. B. Kalyanaraman, J. Joseph, and S. Kalivendi Doxorubicin-induced apoptosis: implications in cardiotoxicity Mol Cell Biochem 235 2002 119 124
7. N. Kalay, E. Basar, and I. Ozdogru Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262
8. G. Feuerstein, and R.R. Ruffolo Jr. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure Adv Pharmacol 42 1998 611 615
9. J. Cheng, K. Kamiya, and I. Kodama Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential Cardiovasc Drug Rev 19 2001 152 171
10. B. Dulin, and W.T. Abraham Pharmacology of carvedilol Am J Cardiol 6 2004 3 6
11. P. Spallarossa, S. Garibaldi, P. Altieri, P. Fabbi, V. Manca, and S. Nasti Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro J Mol Cell Cardiol 37 2004 837 846
12. S. Ibrahim, M. Barakat, and H. Helmy Modulating effect of carvedilol on doxorubicin-induced cardiomyopathy and hepatic damage J Am Sci 6 2010 20 32
13. X. Bosch, J. Esteve, M. Sitges, T.M. de Caralt, A. Domenech, and J.T. Ortiz Prevention of chemotherapy-induced left ventricular dysfunction with enalapril and carvedilol: rationale and design of the overcome trial J Card Fail 17 2011 643 648
14. J.S. Gottdiener, J. Bednarz, and R. Devereux American Society of Echocardiography recommendations for use of echocardiography in clinical trials J Am Soc Echocardiogr 17 2004 1086 1119
15. J. d'Hooge, A. Heimdal, and F. Jamal Regional strain and strain rate measurements by cardiac ultrasound: principles, implementation and limitations Eur J Echocardiogr 1 2000 154 170
16. R.J. Henry Colorimetric determination of lactic dehydrogenase R.J. Henery, Clinical chemistry: principles and techniques 2nd ed. 1974 Harper and Row Hagerstown, NJ 819 831
17. B. Abbot Creatinine kinase A. Kaplan, Clinical chemistry 1984 Mosby St Louis, Toronto, Princeton 1112 1116
18. R. Migrino, D. Aggarwal, and E. Konorev Early detection of doxorubicin cardiomyopathy using 2-dimensional strain echocardiography. J Ultrasound Med Biol 34 2009 208 214
19. J. McKillop, M. Bristow, and M. Goris Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity Am Heart J 106 1983 1048 1056
20. G. Tjeerdsma, M. Meinardi, and W. van der Graaf Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables J Heart 81 1999 419 423
21. M.S. Ewer, M.K. Ali, and H.R. Gibbs Cardiac diastolic function in pediatric patients receiving doxorubicin Acta Oncol 33 1994 645 649
22. M. Galderisi, F. Marra, and R. Esposito Cancer therapy and cardiotoxicity: the need of serial Doppler echocardiography J Cardiovasc Ultrasound 5 2007 1 14
23. B. Marchandise, E. Schroeder, and A. Body Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics Am Heart J 118 1989 92 98
24. A. Giantris, L. Abdurrahman, and A. Hinkle Anthracycline-induced cardiotoxicity in children and young adults Crit Rev Oncol Hematol J 27 1998 53 68
25. M. Grenier, and S. Lipshultz Epidemiology of anthracycline cardiotoxicity in children and adults Semin Oncol 25 1998 72 85
26. F. Bu'Lock, M. Mott, and A. Oakhill Left ventricular diastolic filling patterns associated with progressive anthracycline-induced myocardial damage: a prospective study Pediatr Cardiol J 20 1999 252 263
27. L. Elbl, H. Hrstkova, and V. Chaloupka The late consequences of anthracycline treatment on left ventricular function after treatment for childhood cancer Eur J Pediatr 162 2003 690 696
28. Cheung Y, Hong W, Chan CF, et al. Left ventricular myocardial deformation and mechanical dyssynchrony in children with normal ventricular shortening fraction after anthracycline therapy. Available at http://heart.bmj.com/content/ early/2010/05/29/hrt.
29. R. Abreu, D. Santos, and A. Moreno Effects of carvedilol and its analog BM-910228 on mitochondrial function and oxidative stress J Pharmacol Exp Ther 295 2000 1022 1030
30. M. Arai, K. Tomaru, and T. Takizawa Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits J Mol Cell Cardiol 30 1998 243 254
31. 2+-ATPase2 gene transcription through modification of Sp1 binding J Biochem Biophys Res Commun 328 2005 116 124
32. N. Kalay, E. Basar, and I. Ozdogru Protective Effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262